A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Advances. 2023; 7:2590-2605.
.Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatric Neurology. 2023; 143:34-43.
.Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics. 2023; 385:106-116.
.2023; 21:ia17.
. Abstract IA17: Use of RAS isoforms in nerve tumors. Molecular cancer research : MCR.Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene: Including Oncogene Reviews. 2023; 42:1038-1047.
.Merlin tumor suppressor function is regulated by PIP2-mediated dimerization. Editor, van der Wel P. PloS one. 2023; 18:e0281876.
.Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023; 26:106096.
.Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI insight. 2022; 7:e154513.
.The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents. Clinical Cancer Research. 2022; 28:3185-3195.
.P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. eLife. 2022; 11:e73511.
.Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Research. 2021; 80:4720-4730.
.Cdc42 activity in Sertoli cells is essential for maintenance of spermatogenesis. Cell Reports. 2021; 37:109885.
.Purinergic signaling in peripheral nervous system glial cells. Glia. 2021; 69:1837-1851.
.WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene: Including Oncogene Reviews. 2021; 40:4229-4241.
.Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports. 2021; 23:45.
.Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 2021; 13:1584.
.NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39:797-806.
.Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances. 2021; 7:eabd7459.
.MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene: Including Oncogene Reviews. 2021; 40:951-963.
.A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine. 2020; 22:1786-1793.
.Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase. Proceedings of the National Academy of Sciences of USA. 2020; 117:22506-22513.
.After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncology Advances. 2020; 2:i23-i32.
.HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. The Journal of Clinical Investigation. 2020; 130:3848-3864.
.Distinct Roles for Rac1 in Sertoli Cell Function during Testicular Development and Spermatogenesis. Cell Reports. 2020; 31:107513.
.Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. American Journal of Cancer Research. 2020; 10:856-869.
.The sixth international RASopathies symposium: Precision medicine-From promise to practice. American Journal of Medical Genetics, Part A. 2020; 182:597-606.
.The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. MOLECULES AND CELLS. 2020; 43:145-152.
.The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. MOLECULES AND CELLS. 2020; 43:153-159.
.NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.
.Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. Scientific Reports. 2019; 9:19704.
.iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform. BMC Genomics. 2019; 20:177.
.2019; 21:vi267.
. TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1. Neuro-Oncology.2019; 21:vi33.
. CBMT-05. GENETIC AND EPIGENETIC MECHANISMS REGULATING SCD INHIBITOR SENSITIVITY IN GLIOBLASTOMA. Neuro-Oncology.Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Clinical Cancer Research. 2019; 25:4117-4127.
.First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics. American Journal of Medical Genetics, Part A. 2019; 179:1091-1097.
.The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin. Editor, Sommer C. PloS one. 2019; 14:e0216527.
.RUNX represses Pmp22 to drive neurofibromagenesis. Science Advances. 2019; 5:eaau8389.
.Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. Science Signaling. 2019; 12:eaau8749.
.STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene: Including Oncogene Reviews. 2019; 38:2876-2884.
.Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI insight. 2019; 4:e98601.
.Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. Pediatric Blood and Cancer. 2019; 66:e27520.
.